Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Assets (2016 - 2025)

Historic Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $577.1 million.

  • Viridian Therapeutics, Inc.\DE's Assets fell 2523.15% to $577.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.1 million, marking a year-over-year decrease of 2523.15%. This contributed to the annual value of $742.4 million for FY2024, which is 5137.98% up from last year.
  • Viridian Therapeutics, Inc.\DE's Assets amounted to $577.1 million in Q3 2025, which was down 2523.15% from $582.3 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Assets' 5-year high stood at $771.9 million during Q3 2024, with a 5-year trough of $118.2 million in Q2 2021.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Assets averaged around $421.2 million, with its median value being $435.1 million (2022).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Assets surged by 57372.77% in 2021 and then tumbled by 2538.09% in 2023.
  • Viridian Therapeutics, Inc.\DE's Assets (Quarter) stood at $203.7 million in 2021, then surged by 113.58% to $435.1 million in 2022, then increased by 12.72% to $490.4 million in 2023, then surged by 51.38% to $742.4 million in 2024, then dropped by 22.26% to $577.1 million in 2025.
  • Its last three reported values are $577.1 million in Q3 2025, $582.3 million for Q2 2025, and $661.0 million during Q1 2025.